ArticleAnalytical and bioanalytical chemistry2021
Upconverting nanoparticle reporter-based highly sensitive rapid lateral flow immunoassay for hepatitis B virus surface antigen.
Article in Analytical and bioanalytical chemistry, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 51 citations in OpenAlex.
- Beads-on-a-Tip testing for ultrasensitive antigen detection across a large dynamic range.Smart molecules : open access · 2026Article
- Magnetically Retrievable Platinum Nanoreporters for Efficient Lateral Flow Immunoassay in Complex Bio-Samples.Small (Weinheim an der Bergstrasse, Germany) · 2026Article
- Breaking barriers through driving innovation: sensitivity enhancement strategies for lateral flow assays.Mikrochimica acta · 2025Review
- Advancing HBV Diagnostics: The Role of Ultrasensitive HBsAg Testing.Diagnostics (Basel, Switzerland) · 2025Review
- High-Sensitivity Detection of Urinary Extracellular Vesicles With Upconverting Nanoparticle-Based Lateral Flow Immunoassay.Journal of extracellular biology · 2025Article
- The Application of Anisotropically Collapsing Gels, Deep Learning, and Optical Microscopy for Chemical Characterization of Nanoparticles and Nanoplastics.Langmuir : the ACS journal of surfaces and colloids · 2025Article
- Advancing foodborne pathogen detection: a review of traditional and innovative optical and electrochemical biosensing approaches.Mikrochimica acta · 2025Review
- Upconverting Nanoparticle-based Enhanced Luminescence Lateral-Flow Assay for Urinary Biomarker Monitoring.ACS applied materials & interfaces · 2024Article
- Point-of-care detection of Monkeypox virus clades using high-performance upconversion nanoparticle-based lateral flow assay.Mikrochimica acta · 2024Article
- Improved sensitivity and automation of a multi-step upconversion lateral flow immunoassay using a 3D-printed actuation mechanism.Analytical and bioanalytical chemistry · 2024Article
- Optimization of a rapid and sensitive nucleic acid lateral flow biosensor for hepatitis B virus detection.Molecular biology reports · 2023Article
- Lateral Flow Assay for Hepatitis B Detection: A Review of Current and New Assays.Micromachines · 2023Review
- Recent Trends in Lateral Flow Immunoassays with Optical Nanoparticles.International journal of molecular sciences · 2023Review
- Plasmon Modulated Upconversion Biosensors.Biosensors · 2023Review
- Colorimetric and Raman dual-mode lateral flow immunoassay detection of SARS-CoV-2 N protein antibody based on Ag nanoparticles with ultrathin Au shell assembled onto FeAnalytical and bioanalytical chemistry · 2023Article
- Advances in upconversion luminescence nanomaterial-based biosensor for virus diagnosis.Exploration (Beijing, China) · 2022Review
- Lateral Flow Immunoassay Based on Time-Resolved Fluorescence Microspheres for Rapid and Quantitative Screening CA199 in Human Serum.International journal of molecular sciences · 2022Article
- Photoluminescent Molecules and Materials as Diagnostic Reporters in Lateral Flow Assays.ACS applied bio materials · 2022Article
- Latest Trends in Lateral Flow Immunoassay (LFIA) Detection Labels and Conjugation Process.Frontiers in bioengineering and biotechnology · 2022Review
- Lateral flow assays (LFA) as an alternative medical diagnosis method for detection of virus species: The intertwine of nanotechnology with sensing strategies.Trends in analytical chemistry : TRAC · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 2 countries.
Funding
Abstract
Detection of hepatitis B Virus surface antigen (HBsAg) is an established method for diagnosing both acute and chronic hepatitis B virus (HBV) infection. In addition to enzyme immunoassays (EIAs), rapid diagnostic tests (RDTs) are available for the detection of HBsAg in resource-poor settings. However, the available RDTs have inadequate sensitivity and therefore are not suitable for diagnosis of patients with low levels of HBsAg and for blood screening. To provide a high-sensitivity RDT, we developed a lateral flow immunoassay (LFIA) for HBsAg utilizing upconverting nanoparticle (UCNP) reporter. The UCNP-LFIA can use whole blood, serum, or plasma and the results can be read in 30 min using a reader device. When compared with a commercial conventional visually read LFIA, the developed UCNP-LFIA had a Limit of Detection (LoD) of 0.1 IU HBsAg/ml in spiked serum, whereas the LoD of the conventional LFIA was 3.2 IU HBsAg/ml. The developed UCNP-LFIA fulfills the WHO criterion for blood screening (LoD ≤ 0.13 IU HBsAg/ml) in terms of LoD. The UCNP-LFIA and conventional LFIA were evaluated with well-characterized sample panels. The UCNP-LFIA detected 20/24 HBsAg-positive samples within the HBsAg Performance Panel and 8/10 samples within the Mixed Titer Performance Panel, whereas the conventional LFIA detected 8/24 and 4/10 samples in these panels, respectively. The performance of the assays was further evaluated with HBsAg-positive (n = 108) and HBsAg-negative (n = 315) patient samples. In comparison with a central laboratory test, UCNP-LFIA showed 95.4% (95% CI: 89.5-98.5%) sensitivity whereas sensitivity of the conventional LFIA was 87.7% (95%CI: 79.9-93.3%).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.